<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646724</url>
  </required_header>
  <id_info>
    <org_study_id>fuzhough0712</org_study_id>
    <secondary_id>fuzhough0712</secondary_id>
    <nct_id>NCT00646724</nct_id>
  </id_info>
  <brief_title>Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients</brief_title>
  <official_title>Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuzhou General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuzhou General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the safety and efficacy of Cotransplantation of Islet and Mesenchymal
      Stem Cell in Type 1 Diabetic Patients. The researchers hypothesize that additional
      Mesenchymal Stem Cell infusion can benefit the promising clinical islet transplantation
      through the following mechanisms: protection of islet from inflammatory damage, immunological
      modulation, engraftment promotion, thus decrease or eliminate the need of exogenous insulin
      and improve Î²-cell function.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exogenous insulin requirement</measure>
    <time_frame>5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose and C-peptide levels</measure>
    <time_frame>5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>liver function</measure>
    <time_frame>5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kidney function</measure>
    <time_frame>5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portal vein Ultrasound</measure>
    <time_frame>1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>autoantibodies</measure>
    <time_frame>5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Blood Count</measure>
    <time_frame>5</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cotransplantation of islet and mesenchymal stem cell</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cotransplantation of islet and mesenchymal stem cell</intervention_name>
    <description>islet of allograft and MSCs of autograft</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients age 18 to 60 years of age

          -  Ability to provide written informed consent

          -  Manifest signs and symptoms that are severe enough to be incapacitating

          -  Patients with poor diabetes control (HbA1c &gt; 7% but &lt; 12%)

          -  Progressive diabetic complications

        Exclusion Criteria:

          -  age &lt; 18 years or &gt; 60 years

          -  diabetic history &lt; 5 years

          -  BMI &gt; 27

          -  body weight &gt; 80 kg

          -  exogenous insulin requirement &gt; 1 unit/kg/day

          -  severe anemia (male &lt; 8 g/dl, female &lt; 7 g/dl)

          -  low white blood cell count (&lt; 3000/dl)

          -  liver dysfunction

          -  Active infection including hepatitis B, hepatitis C, HIV, or TB

          -  panel reactive antibody &gt; 20%

          -  Any medical condition that, in the opinion of the investigator, will interfere with
             the safe completion of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianming Tan, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuzhou General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianming Tan, Professor</last_name>
    <phone>008613375918000</phone>
    <email>TANJM156@YAHOO.COM.CN</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuzhou General Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2008</study_first_submitted>
  <study_first_submitted_qc>March 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2008</study_first_posted>
  <last_update_submitted>June 15, 2011</last_update_submitted>
  <last_update_submitted_qc>June 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>FUZHOU GENERAL HOSPITAL</name_title>
    <organization>FUZHOU GENERAL HOSPITAL</organization>
  </responsible_party>
  <keyword>Islets of Langerhans Transplantation</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

